Metronidazol Bradex (Metronidazole)

Metronidazole is reduced inside anaerobic microorganisms, forming nitro radicals that damage DNA and inhibit nucleic acid synthesis. This disruption leads to loss of cellular function and ultimately death of the susceptible bacteria or protozoa.

The specific dose and duration of Metronidazol Bradex are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other individual factors. No standard dosing is provided here.

Safety data for Metronidazol Bradex in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit outweighs the potential risk. Breastfeeding mothers should consult a healthcare professional, as the drug may be excreted in milk.

To order Metronidazol Bradex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Metronidazol Bradex delivers metronidazole intravenously, offering rapid systemic exposure compared with oral nitroimidazoles such as tinidazole or ornidazole. IV administration is advantageous for severe infections, patients unable to take oral medication, or when high plasma concentrations are required quickly.

Metronidazol Bradex must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, inspect for particulate matter and ensure the solution is at room temperature if required by the clinical protocol.

Metronidazol Bradex is given by intravenous infusion or injection under the supervision of a qualified healthcare professional. The infusion rate and dilution are determined by the prescriber and institutional guidelines to achieve the desired therapeutic concentration while minimizing adverse effects.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions (including anaphylaxis), Stevens‑Johnson syndrome, hepatotoxicity, and pancytopenia. Patients should be monitored for neurological symptoms, skin changes, liver function abnormalities, and blood count alterations throughout therapy.

Metronidazol Bradex should be avoided in patients with known hypersensitivity to metronidazole or other nitroimidazoles, those with severe hepatic impairment where benefit does not outweigh risk, and individuals who cannot abstain from alcohol during treatment due to the risk of a disulfiram‑like reaction.